For payers

Section 3201 of the CARES Act amended section 6001 of the FFCRA to include a range of diagnostic items and services for the detection of SARS-CoV-2 or the diagnosis of COVID-19 that plans and issuers (‘plans’) must cover without any cost-sharing requirements, prior authorization, or other medical management requirements. Section 3202(a) of the CARES Act requires plans providing coverage for these items and services to reimburse providers an amount that equals the negotiated rate or, if the plan does not have a negotiated rate with the provider, the cash price for such service that is listed by the provider on its public website.

The cash prices for our services related to COVID-19 testing and diagnosis can be found here. In alignment with the CARES Act, there are no instances in which patients would be held responsible for these charges, or for a part of these charges.